Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
J Urol
; 196(4): 1021-9, 2016 Oct.
Article
en En
| MEDLINE
| ID: mdl-27317986
ABSTRACT
PURPOSE:
Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and progression. Risk stratification should influence evaluation, treatment and surveillance. This guideline attempts to provide a clinical framework for the management of NMIBC. MATERIALS ANDMETHODS:
A systematic review utilized research from the Agency for Healthcare Research and Quality (AHRQ) and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A, B, or C and were designated as Strong, Moderate, and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions.(1)RESULTS:
A risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk. Importantly, the evaluation and treatment algorithm takes into account tumor characteristics and uniquely considers a patient's response to therapy. The 38 statements vary in level of evidence, but none include Grade A evidence, and many were Grade C.CONCLUSION:
The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Sociedades Médicas
/
Urología
/
Neoplasias de la Vejiga Urinaria
/
Guías de Práctica Clínica como Asunto
Tipo de estudio:
Diagnostic_studies
/
Guideline
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
J Urol
Año:
2016
Tipo del documento:
Article